Key result
Psilocybin prolongs QTcF by ~2 ms, indicating limited proarrhythmic risk.
Why the study?
Psilocybin is being developed for treating major depressive disorder and is dephosphorylated to psilocin upon absorption, requiring assessment of the potential for a psilocin proarrhythmic effect.
Answers are grounded in this paper and cite their sources.
Supports limited QTc effects at clinical psilocybin doses; leaves open supraclinical risk and need for randomized confirmation.
Psilocybin is being developed for treating major depressive disorder. Psilocybin is readily dephosphorylated to psilocin upon absorption. The potential for psilocin proarrhythmic effect was assessed using a concentration-QTc interval (C-QTc) analysis from an open-label single ascending dose study of psilocybin. Psilocybin doses ranged from 0.3 to 0.6 mg/kg. This trial showed a significant but shallow C-QTc relationship. At the clinical dose of 25 mg, the mean psilocin maximum concentration is 18.7 ng/mL, and the associated mean (upper 90% confidence interval of mean) QTcF change is 2.1 (6.6) milliseconds. Given the short half-life of psilocin of about 4 hours, there would be no accumulation after monthly oral doses used in clinical trials. The upper limit of the 90% confidence interval of the model-predicted mean ΔQTcF crossed 10 milliseconds at a psilocin concentration of 31.1 ng/mL. At a supraclinical psilocin maximum concentration of about 60 ng/mL, ΔQTcF remains low, with a mean (upper limit of the 90% confidence interval) of 9.1 (17.9) milliseconds. This analysis enabled the characterization of the C-QTc relationship and prediction of QTc prolongation at the expected clinical and possible higher psilocybin doses.
No takes yet. Share an insight, caveat, or question.
Dahmane et al. (2020) conducted a review in Major depressive disorder / Psilocybin multi-organ toxicity (n=12). Psilocybin was evaluated on QTcF interval change (ΔQTcF) at the clinical dose of 25 mg. Psilocybin at a clinical dose produced a mean QTcF change of 2.1 ms at a mean maximum psilocin concentration of 18.7 ng/mL, indicating limited proarrhythmic risk.
Synapse has enriched 10 related papers. Consider them for comparative context: